Celldex announces upcoming presentation of barzolvolimab Phase 2 results

Celldex Therapeutics announced that an abstract describing 12 week results from the Company’s Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria refractory to antihistamines, including patients with biologic-refractory disease, has been accepted as a late breaking oral presentation at the American Academy of Allergy, Asthma & Immunology, AAAI, Annual Meeting 2024 being held in Washington, DC on February 23-26, 2024. Abstracts will be available on the meeting website today, February 5, 2024. The abstract is comprised of the topline 12-week primary endpoint results the Company disclosed on November 6, 2023.